Literature DB >> 9473130

Endothelium and cannabinoid receptor involvement in levcromakalim vasorelaxation.

R White1, C R Hiley.   

Abstract

Levcromakalim was more potent at relaxing rat small mesenteric arteries with endothelium (EC50, 84+/-10 nM) than denuded vessels (EC50, 779+/-101 nM). The cannabinoid receptor antagonist SR 141716A (N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-me thyl-1H-pyrazole-3-carboxamide hydrochloride; 1 microM) shifted the levcromakalim concentration/response curve 7.6-fold rightwards in intact vessels but had no effect in de-endothelialised vessels. Similar effects occurred with pinacidil. Combination of the K+ channel blockers apamin (1 microM) and charybdotoxin (100 nM) shifted the levcromakalim concentration/response curve 3-fold rightwards only in intact vessels. It is concluded that levcromakalim and pinacidil relax mesenteric arteries partly by releasing a relaxing factor from endothelium, possibly an endogenous cannabinoid.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9473130     DOI: 10.1016/s0014-2999(97)01397-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  A xanthine-based KMUP-1 with cyclic GMP enhancing and K(+) channels opening activities in rat aortic smooth muscle.

Authors:  B N Wu; R J Lin; C Y Lin; K P Shen; L C Chiang; I J Chen
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

2.  Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts.

Authors:  William R Ford; Stuart A Honan; Richard White; C Robin Hiley
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Cellular mechanisms by which adenosine induces vasodilatation in rat skeletal muscle: significance for systemic hypoxia.

Authors:  P T Bryan; J M Marshall
Journal:  J Physiol       Date:  1999-01-01       Impact factor: 5.182

4.  Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat.

Authors:  P M Hoi; C Visintin; M Okuyama; S M Gardiner; S S Kaup; T Bennett; D Baker; D L Selwood; C R Hiley
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

Review 5.  Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

Authors:  Hester van Diepen; Eberhard Schlicker; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-25       Impact factor: 3.000

6.  Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.

Authors:  Akihiro Asai; Nita Sahani; Masao Kaneki; Yasuyoshi Ouchi; J A Jeevendra Martyn; Shingo Egusa Yasuhara
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.